BPC-157 / TB-500 Blend

The BPC-157 / TB-500 blend combines two synthetic research peptides that are marketed together for healing and recovery. Neither component is approved by the FDA for any use, both are studied almost entirely in animals rather than humans, and both are banned in sport by the World Anti-Doping Agency. This page is educational information, not medical advice. It does not endorse using these materials, and any decision about your health should be made with a licensed clinician.

What is BPC-157 / TB-500 Blend?#

This is not a single drug but a mixture of two separate peptides that vendors sell pre-combined:

• BPC-157 (sometimes called Body Protection Compound-157) is a synthetic chain of 15 amino acids. Its sequence is derived from a fragment of a protein found in gastric juice. It does not exist as a complete, naturally occurring molecule in the body in this form.
• TB-500 is a synthetic peptide related to thymosin beta-4, a naturally occurring protein involved in cell movement and tissue repair. The names "TB-500" and "thymosin beta-4" are often used interchangeably by sellers, though TB-500 typically refers to a synthetic fragment rather than the full natural protein.

The two are blended because each has been promoted for soft-tissue and recovery purposes, and sellers suggest their actions might complement each other. It is important to understand that the blend as a product has not itself been the subject of published human studies; the rationale for combining them is largely a marketing convention rather than an established, evidence-based protocol.

How does BPC-157 / TB-500 Blend work?#

The proposed mechanisms come from preclinical (cell and animal) research on each peptide individually:

• BPC-157 has been reported in animal studies to interact with the nitric oxide (NO) signaling system, to promote the formation of new blood vessels (angiogenesis), and to show antioxidant activity. Reviews describe effects on the healing of skin, muscle, tendon, ligament, and gut tissue in rodents.
• TB-500 / thymosin beta-4 is described as a regulator of the protein actin inside cells, which influences how cells migrate to a wound. Animal and laboratory work links it to angiogenesis, reduced inflammation, and faster re-epithelialization (skin closing over) of wounds.

These are proposed mechanisms based largely on animal models. They have not been confirmed to produce safe or meaningful effects in humans, and laboratory mechanisms frequently fail to translate into real-world clinical benefit.

What is BPC-157 / TB-500 Blend studied for?#

Most claims trace back to preclinical research on the two peptides separately. The table below summarizes common research themes and how strong the human evidence is.

A notable limitation: a large share of the published BPC-157 literature comes from a single research group, which makes independent confirmation difficult.

Is BPC-157 / TB-500 Blend legal and FDA-approved?#

Neither component is FDA-approved.

• FDA status: Neither BPC-157 nor TB-500 is an FDA-approved drug, and neither is a lawful dietary supplement ingredient. In September 2023 the FDA placed BPC-157 and the thymosin beta-4 fragment (TB-500) in Category 2 of its review of bulk drug substances for compounding under section 503A — substances the agency considered to raise significant safety concerns, citing issues such as immunogenicity and impurities. In April 2026 the FDA announced it was removing these peptides from Category 2, but it has been explicit that removal does not make them FDA-approved or eligible for compounding; they remain unapproved drugs pending further regulatory review. Products are frequently sold labeled "research use only" or "not for human consumption."
• Sport status: Both BPC-157 and TB-500 are on the WADA Prohibited List under category S0 (Non-approved substances), which covers substances not approved by any government regulatory health authority for human therapeutic use. They are banned at all times, in and out of competition, and athletes have received multi-year sanctions for their use. Military service members are also warned against products containing these peptides.

Selling, marketing, or buying these as human-use products is legally fraught, and the "research chemical" labeling does not make human use safe or lawful.

How is BPC-157 / TB-500 Blend dosed in research?#

There is no validated human dose for BPC-157, TB-500, or the blend. Because adequate human trials have not been conducted, no one has established a dose that is known to be safe or effective, and no governing health authority has issued dosing guidance.

WikiPeps does not publish dosing protocols or amounts for these peptides. Any question about whether a peptide could be appropriate, and in what form or amount, should be directed to a licensed clinician who can weigh your individual medical history and the substantial unknowns involved.

How is BPC-157 / TB-500 Blend reconstituted?#

These peptides are typically supplied as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic or sterile water before any handling. The frontmatter on this page includes a generic, education-only overview of the reconstitution steps, with no volumes or concentrations. For a fuller walkthrough of sterile technique, supplies, and storage, see our general guide at /learn/guides/how-to-reconstitute-a-peptide.

Reconstitution instructions describe laboratory handling only. They are not an endorsement of use and do not substitute for guidance from a licensed clinician.

What are the safety considerations?#

• Unknown human safety. With no adequate human trials, the long-term risks, drug interactions, and safe dose (if any) are unknown for both peptides and especially for the combination.
• Possible tumor-growth concern. Because these peptides are reported to promote new blood-vessel growth, regulators and anti-doping bodies have raised the theoretical concern that they could also support the growth of an existing, undetected tumor. This has not been resolved in humans.
• Product quality risk. Material sold as a research chemical is not manufactured to pharmaceutical standards. Purity, sterility, correct identity, and accurate labeling are not guaranteed, and contamination or mislabeling is a real possibility.
• Injection risks. These products are typically injected after reconstitution, which carries risks of infection, injection-site reactions, and harm from non-sterile technique.
• Regulatory and sport consequences. Use can result in anti-doping sanctions for athletes and is incompatible with rules for military service members and many employers.
• Not a substitute for care. Self-treating an injury or medical condition with an unapproved peptide may delay appropriate, evidence-based medical care.

If you are considering anything in this category, talk with a licensed clinician first. If you experience a reaction or adverse event, seek medical attention.

The bottom line#

The BPC-157 / TB-500 blend pairs two synthetic peptides that are both unapproved research chemicals, not medicines. The evidence for either is largely preclinical, the combination has no published human studies, and both are banned in sport by WADA. Human safety, effectiveness, and dosing are not established. This page is educational only and is not medical advice; decisions about your health should be made with a qualified, licensed clinician.